Rapid regression of disc neovascularization in a patient with proliferative diabetic retinopathy following adjunctive intravitreal bevacizumab
SJ Bakri, MJ Donaldson, TP Link - Eye, 2006 - nature.com
SJ Bakri, MJ Donaldson, TP Link
Eye, 2006•nature.comBevacizumab (Avastin, Genentech Inc., San Francisco, CA, USA) is a recombinant
humanized monoclonal IgG1 antibody that inhibits human vascular endothelial growth factor
(VEGF). It has been administered intravitreally in VEGF-mediated diseases such as
choroidal neovascularization1 and central retinal vein occlusion. 2 VEGF plays a major role
in mediating neovascularization in eyes with proliferative diabetic retinopathy (PDR). 3 We
describe a patient who had dramatic regression of retinal neovascularization 1 week …
humanized monoclonal IgG1 antibody that inhibits human vascular endothelial growth factor
(VEGF). It has been administered intravitreally in VEGF-mediated diseases such as
choroidal neovascularization1 and central retinal vein occlusion. 2 VEGF plays a major role
in mediating neovascularization in eyes with proliferative diabetic retinopathy (PDR). 3 We
describe a patient who had dramatic regression of retinal neovascularization 1 week …
Bevacizumab (Avastin, Genentech Inc., San Francisco, CA, USA) is a recombinant humanized monoclonal IgG1 antibody that inhibits human vascular endothelial growth factor (VEGF). It has been administered intravitreally in VEGF-mediated diseases such as choroidal neovascularization1 and central retinal vein occlusion. 2 VEGF plays a major role in mediating neovascularization in eyes with proliferative diabetic retinopathy (PDR). 3 We describe a patient who had dramatic regression of retinal neovascularization 1 week following adjunctive intravitreal bevacizumab.
nature.com